Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$14.26 USD
-0.14 (-0.97%)
Updated May 2, 2024 04:00 PM ET
After-Market: $14.22 -0.04 (-0.28%) 6:32 PM ET
4-Sell of 5 4
F Value B Growth B Momentum C VGM
Brokerage Reports
Urogen Pharma [URGN]
Reports for Purchase
Showing records 1 - 20 ( 46 total )
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
UGN-102 Rolling Submission Completion Nears; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Exclusive License to Possible Next-Gen Mitomycin Formulation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for URGN 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
UGN-102 12-Month Data Next Year; 3Q23 Earnings Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
UGN-102 New Drug Application Rolling Submission Timeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Record Revenue, Modest Bottom-Line Beat; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
ATLAS and ENVISION Data Surpass Expectations; Raising PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Favorable Jelmyto Retrospective Study Results Released; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Top-Line Beat, Bottom-Line In-Line; Adjusting Sales Forecast; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Study Results Underscore Jelmyto Utility; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Top-Line Beat; Revenue Growth Guidance Lukewarm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Feasibility Study Shows Potential for UGN-102 In-Home Usage; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Jelmyto and UGN-102 Durability Data; 3Q22 Financials; Adjusting PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
UGN-102 Physician Receptivity and Market Size Look Solid; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Jelmyto In-Use Period Extension Authorized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Jelmyto Sales In-Line; Expenses Controlled; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Jelmyto Novel Administration Route Data; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Financial Results Reported; Lowering PT to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R